ATE458199T1 - Diagnostische marker der akuten koronaren syndrome und ihre verwendungen - Google Patents

Diagnostische marker der akuten koronaren syndrome und ihre verwendungen

Info

Publication number
ATE458199T1
ATE458199T1 AT06002477T AT06002477T ATE458199T1 AT E458199 T1 ATE458199 T1 AT E458199T1 AT 06002477 T AT06002477 T AT 06002477T AT 06002477 T AT06002477 T AT 06002477T AT E458199 T1 ATE458199 T1 AT E458199T1
Authority
AT
Austria
Prior art keywords
immunoassay
subject
cardiac troponin
threshold level
acute coronary
Prior art date
Application number
AT06002477T
Other languages
English (en)
Inventor
Gunars E Valkirs
Jeffrey R Dahlen
Howard Kirchick
Kenneth F Buechler
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosite Inc filed Critical Biosite Inc
Application granted granted Critical
Publication of ATE458199T1 publication Critical patent/ATE458199T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Error Detection And Correction (AREA)
AT06002477T 2001-05-04 2002-05-04 Diagnostische marker der akuten koronaren syndrome und ihre verwendungen ATE458199T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28887101P 2001-05-04 2001-05-04
US31564201P 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
ATE458199T1 true ATE458199T1 (de) 2010-03-15

Family

ID=26965308

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06002477T ATE458199T1 (de) 2001-05-04 2002-05-04 Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
AT02734211T ATE439588T1 (de) 2001-05-04 2002-05-04 Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02734211T ATE439588T1 (de) 2001-05-04 2002-05-04 Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs

Country Status (8)

Country Link
US (2) US7361473B2 (de)
EP (3) EP1322957B1 (de)
JP (3) JP3806694B2 (de)
AT (2) ATE458199T1 (de)
AU (1) AU2002305394A1 (de)
CA (1) CA2414073A1 (de)
DE (2) DE60233301D1 (de)
WO (1) WO2002089657A2 (de)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991907B1 (en) * 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US6627404B1 (en) * 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20040176914A1 (en) * 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
EP1587409B1 (de) * 2002-10-09 2013-01-16 DMI Biosciences, Inc. Diagnose und überwachung von akuten koronaren syndromen
AU2003297583B2 (en) * 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
MXPA05010385A (es) * 2003-03-27 2006-03-08 Childrens Hosp Medical Center Metodo y estuche para detectar el inicio temprano de lesion celular tubular renal.
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004094460A2 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
WO2004097368A2 (en) * 2003-04-28 2004-11-11 Ciphergen Biosystems, Inc. Improved immunoassays
US20070037208A1 (en) * 2003-05-29 2007-02-15 Foote Robert S Method for detecting cardiac ischemia via changes in b-natriuretic peptide levels
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern
CA2563310A1 (en) * 2003-11-07 2005-05-26 Princeton Biochemicals, Inc. Multi-dimensional electrophoresis apparatus
EP1530047A1 (de) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximale Markermoleküle der Arterienthrombose und der Entzündung zur Risikostratifizierung einer koronaren Herzkrankheit
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US20080175191A1 (en) * 2004-02-23 2008-07-24 Siemens Aktiengesellschaft Method, Intermediate Station and Central Control Unit For the Packet-Switched Data Transmission in a Self-Organizing Radio Network
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
DE102004028303A1 (de) 2004-06-11 2005-12-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Nachweis von Analyten
CA2567738C (en) 2004-06-15 2010-12-21 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
EP1615035B1 (de) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
PL1831699T3 (pl) * 2004-12-20 2010-04-30 Antibodyshop As Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
EP1691200A1 (de) * 2005-02-14 2006-08-16 F. Hoffmann-La Roche Ag Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
EP1849009B1 (de) * 2005-01-24 2008-10-29 F. Hoffmann-La Roche AG Verwendung von Herzhormonen zur Diagnose des Kardiovaskuläre Risikos als folge einer Verabreichung von Entzündungshemmern
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
JP2008529702A (ja) 2005-02-21 2008-08-07 国立大学法人佐賀大学 心臓血管疾患のための新規診断マーカーとしての血小板由来マイクロパーティクル
CA2599731A1 (en) * 2005-03-03 2006-09-08 Dmi Biosciences, Inc. Quantification of proteins
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20060240444A1 (en) * 2005-04-21 2006-10-26 Peiguo Chu Detection methods
US7300631B2 (en) * 2005-05-02 2007-11-27 Bioscale, Inc. Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles
CN100422742C (zh) * 2005-05-16 2008-10-01 艾博（武汉）生物技术有限公司 急性心肌梗死早期诊断三合一检测试剂板
US20070003981A1 (en) * 2005-06-29 2007-01-04 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
ES2288358B1 (es) * 2005-07-01 2008-11-16 Proyecto De Biomedicina Cima, S.L. Marcadores de fibrosis.
JP4850001B2 (ja) * 2005-09-05 2012-01-11 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US7399598B2 (en) * 2005-10-14 2008-07-15 Taipei Medical University Diagnosis method of endometriosis by detecting biochemical markers and usage of these biochemical markers
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP2007131548A (ja) * 2005-11-08 2007-05-31 Hirosaki Univ プロテオグリカンの新規医薬用途
EP2431746A1 (de) 2005-11-17 2012-03-21 Biogen Idec MA Inc. Thrombozytenaggregationsprüfungen
US9829494B2 (en) * 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
US20070172888A1 (en) * 2006-01-25 2007-07-26 Klaus Hallermayer Measuring troponin antibodies to assess cardiovascular risk
WO2007103568A2 (en) * 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
DE602006014798D1 (de) 2006-03-24 2010-07-22 Roche Diagnostics Gmbh Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA2648385C (en) * 2006-04-04 2020-09-01 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP6325022B2 (ja) * 2006-04-04 2018-05-16 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
AU2014200749B2 (en) * 2006-04-04 2016-04-14 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP1845379A1 (de) 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Mittel und Verfahren zur Differenzierung kardialer und pulmonaler Ursachen von Atemnot
AU2007244927B2 (en) 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
DE602007007595D1 (en) * 2006-04-24 2010-08-19 Univ Wien Med Ten
EP2021796B1 (de) * 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnose von herz-kreislauf-erkrankung
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US20080118924A1 (en) * 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
WO2007137584A1 (en) 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
EP1882945A1 (de) 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot
ATE511656T1 (de) 2006-08-04 2011-06-15 Hannover Med Hochschule Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP1890153A1 (de) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
EP1901072B1 (de) 2006-09-15 2009-11-25 F. Hoffman-la Roche AG Biochemische Marker für akute Lungenembolie
EP1901073A1 (de) 2006-09-18 2008-03-19 Roche Diagnostics GmbH Natriuretische Peptide zur Diagnose von Herzkomplikationen infolge von Koronarkatheterisierung
DE602006015964D1 (de) * 2006-09-20 2010-09-16 Roche Diagnostics Gmbh Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
PL2084543T3 (pl) 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
EP2095106B1 (de) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenarterienstenose
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
EP1925943A1 (de) 2006-11-21 2008-05-28 F. Hoffman-la Roche AG Vorrichtungen und Verfahren zur Optimierung von diagnostischen and therapeutischen Ansätzen für chronische Arterienerkrankungen basierend auf dem Nachweis von Troponin T und NT-proBNP.
EP2092333B1 (de) 2006-11-28 2013-05-01 Pictor Limited Assay-membran und verfahren zu ihrer verwendung
JP2010517023A (ja) 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
WO2008098734A1 (en) 2007-02-12 2008-08-21 Stefan Hansson Diagnosis and treatment of preeclampsia
US9086408B2 (en) 2007-04-30 2015-07-21 Nexus Dx, Inc. Multianalyte assay
WO2008107201A1 (en) * 2007-03-08 2008-09-12 Roche Diagnostics Gmbh Use of slim-1 in the assessment of heart failure
GB0705223D0 (en) * 2007-03-19 2007-04-25 Univ Sussex Method, apparatus and computer program for analysing medical image data
EP2137538B1 (de) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostischer test auf nierenverletzung
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
JP5570415B2 (ja) * 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
EP1998178A1 (de) * 2007-05-29 2008-12-03 F. Hoffman-la Roche AG H-FABP als Prädiktor für Herzinfarkt
US8691595B2 (en) * 2007-06-22 2014-04-08 B.R.A.H.M.S. Gmbh Method for detecting analytes
CN103123359B (zh) * 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
EP2031397A1 (de) 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactantproteine B und D bei der Unterscheidung der Ursachen für Atemnot
EP2210111A1 (de) 2007-10-10 2010-07-28 Roche Diagnostics GmbH Natriuretisches peptid/troponin-verhältnis zur beurteilung bereits vorhandener myokard-fehlfunktion bei patienten mit akutem koronarsyndrom
US9359633B2 (en) * 2007-11-05 2016-06-07 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
CN101910845A (zh) * 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
AU2008338421A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8440418B2 (en) * 2008-11-18 2013-05-14 Ridge Diagnostics, Inc. Metabolic syndrome and HPA axis biomarkers for major depressive disorder
US7927880B2 (en) 2008-05-21 2011-04-19 Mohan Rajapurkar Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events
WO2009126380A2 (en) * 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
WO2009109982A1 (en) * 2008-03-05 2009-09-11 Mohan Rajapurkar Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events
EP2103943A1 (de) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern
PL2269063T3 (pl) 2008-04-18 2014-04-30 Critical Care Diagnostics Inc Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych
JP5419968B2 (ja) 2008-05-21 2014-02-19 エフ．ホフマン−ラ ロシュ アーゲー 心臓治療を必要とする個体におけるｌ−ｆａｂｐ、ナトリウム利尿ペプチド及び心筋トロポニン
EP2294425B1 (de) 2008-05-23 2013-05-22 The Johns Hopkins University Biomarker für myokardischämie
EP2133696A1 (de) 2008-06-10 2009-12-16 Eberhardt Spanuth Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern
JP2011523072A (ja) * 2008-06-13 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病を有する患者の合併症の評価
EP2148203A1 (de) * 2008-07-23 2010-01-27 BRAHMS Aktiengesellschaft Azurophili-Granulat-Proteasen als Marker bei Herzkrankheiten
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
EP2324358A1 (de) * 2008-07-23 2011-05-25 F. Hoffmann-La Roche AG Überwachung einer antiangiogenesetherapie
WO2010017972A1 (en) 2008-08-13 2010-02-18 Roche Diagnostics Gmbh D-dimer, troponin, nt-probnp for pulmonary embolism
JP5550021B2 (ja) * 2008-08-28 2014-07-16 株式会社島津製作所 血液試料を用いて心筋虚血状態を評価する方法
WO2010045490A2 (en) * 2008-10-15 2010-04-22 Ridge Diagnostics, Inc. Human biomarker hypermapping for depressive disorders
US20120083421A1 (en) * 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
US8457724B2 (en) * 2008-12-11 2013-06-04 Siemens Medical Solutions Usa, Inc. System for heart performance characterization and abnormality detection
JP5660027B2 (ja) * 2009-03-05 2015-01-28 味の素株式会社 クローン病診断試薬
CA2754741C (en) * 2009-03-11 2019-02-12 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
JP2012523009A (ja) * 2009-04-06 2012-09-27 リッジ ダイアグノスティックス，インコーポレイテッド 精神神経疾患の治療をモニタリングするためのバイオマーカー
CN102421917B (zh) 2009-04-29 2014-07-09 阿姆斯特丹大学学术医学中心 对抗、预防和/或测定心力衰竭或心力衰竭的风险的工具和方法
WO2010138610A2 (en) * 2009-05-26 2010-12-02 The Johns Hopkins University Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
JP5678045B2 (ja) * 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
WO2010143422A1 (ja) * 2009-06-10 2010-12-16 国立大学法人 新潟大学 腎疾患の検査方法
WO2011006072A2 (en) * 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
WO2011033034A1 (en) 2009-09-17 2011-03-24 Roche Diagnostics Gmbh Multimarker panel for left ventricular hypertrophy
EP3045918B1 (de) 2009-10-21 2017-12-06 The Scripps Research Institute Verfahren zur verwendung nicht seltener zellen zur erkennung seltener zellen
WO2011057251A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
DK2498796T3 (en) 2009-11-09 2018-03-05 Aal Scient Inc HEART DISEASE TREATMENT
KR20120101064A (ko) * 2009-11-13 2012-09-12 비쥐 메디신, 인코포레이티드 심근 경색의 위험 인자 및 예측
AU2010324544A1 (en) * 2009-11-27 2012-06-21 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
EP2336784B1 (de) 2009-12-18 2017-08-16 Roche Diagnostics GmbH GDF-15 und/oder Troponin T zur Prognose von Nierenausfällen bei Herzinsuffizienzpatienten
EP2529222A4 (de) * 2010-01-26 2013-10-09 Ridge Diagnostics Inc Mehrere biomarkertafeln zur stratifizierung von krankheits-schweregraden und zur überwachung der behandlung von depressionen
US9506909B2 (en) 2010-02-12 2016-11-29 Synlab Medizinisches Versorgungszentrum Heidelberg Gmbh Homoarginine as a biomarker for the risk of mortality
DK2550535T3 (en) * 2010-03-24 2015-07-27 Preelumina Diagnostics Ab HBF AND A1M MARKING AT AN EARLY STAGE
EP2566971B1 (de) 2010-05-06 2019-03-27 Singulex, Inc. Verfahren zur diagnose, einstufung und vorhersage des risikos der entwicklung und identifikation von respondern für die behandlung rheumatoider arthritis
EP2388594A1 (de) 2010-05-17 2011-11-23 Roche Diagnostics GmbH Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2011153127A1 (en) 2010-06-01 2011-12-08 Cardiac Pacemakers, Inc. Integrating sensors and biomarker assays to detect worsening heart failure
EP2596119B8 (de) 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Verfahren zum nachweis seltener subpopulationen von zellen und hochreiner zusammensetzungen aus zellen
CN101942416B (zh) * 2010-07-23 2012-03-28 中国医学科学院放射医学研究所 抗人心肌肌钙蛋白i特异性单克隆抗体及其制备方法
WO2012018535A2 (en) * 2010-07-26 2012-02-09 Wellness Indicators, Inc. Wellness panel
WO2012020045A1 (en) 2010-08-10 2012-02-16 Roche Diagnostics Gmbh Method for selecting patients with stable coronary artery disease for pci or medical treatment
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2367006A1 (de) 2010-08-24 2011-09-21 Roche Diagnostics GmbH Mittel und Verfahren auf PLGF-Basis zur Diagnose kardialer Ursachen bei akuten Entzündungen
CN105044349B (zh) 2010-08-26 2018-04-06 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2439535A1 (de) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2
EP2447720A1 (de) 2010-10-26 2012-05-02 Roche Diagnostics GmbH sFlt1 und Lungenkomplikationen
US8868168B2 (en) 2010-11-11 2014-10-21 Siemens Medical Solutions Usa, Inc. System for cardiac condition characterization using electrophysiological signal data
US8818494B2 (en) 2010-11-29 2014-08-26 Siemens Medical Solutions Usa, Inc. System for ventricular function abnormality detection and characterization
EP2383579A1 (de) 2010-12-17 2011-11-02 F. Hoffmann-La Roche AG sFlt-1, Kardiotroponine und natriuretische Peptide beim Nachweis einer Therapie mit HER-2-Inhibitoren
JP5937106B2 (ja) * 2011-01-20 2016-06-22 サイレックス ラボラトリーズ，エルエルシー グルテン感受性の検出およびグルテン感受性とセリアック病を鑑別するための方法ならびに装置
GB2490652A (en) * 2011-04-18 2012-11-14 Microtest Matrices Ltd Methods of quantifying antibodies, especially IgE antibodies in a sample
US8754044B2 (en) 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
US8684942B2 (en) 2011-05-25 2014-04-01 Siemens Medical Solutions Usa, Inc. System for cardiac impairment detection based on signal regularity
EP2385373A1 (de) 2011-07-01 2011-11-09 F. Hoffmann-La Roche AG Natriuretische Peptide bei der Schwangerschaft
US20120258477A1 (en) * 2011-07-25 2012-10-11 Northwestern University Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease
EP2581040A1 (de) 2011-10-10 2013-04-17 Roche Diagnostics GmbH TNT-basiertes Herzhypertrophierisiko im Zusammenhang mit physiologischem Training und Führung in Athleten
BR112014007007B1 (pt) 2011-10-17 2022-04-19 F. Hoffmann-La Roche Ag Método in-vitro para diferenciação precoce da apoplexia isquêmica cardioembólica, uso de uma troponina cardíaca e dispositivo de diferenciação precoce da apoplexia isquêmica cardioembólica
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
DK2780717T3 (en) 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP4086283A1 (de) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm)-antikörper oder anti-adm-antikörperfragment oder anti-adm-non-ig-gerüst zur verhinderung oder linderung einer organdysfunktion oder eines organversagens bei einem patienten mit einer chronischen oder akuten krankheit oder einem akuten leiden
EP2780370B1 (de) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm)-antikörper oder anti-adm-antikörperfragment oder anti-adm-non-ig-gerüst zur verwendung in der therapie einer akuten erkrankung bei einem patienten zur stabilisierung des kreislaufs
CN104094121B (zh) 2011-12-01 2016-10-26 霍夫曼-拉罗奇有限公司 用于诊断中风的nt-原anp和nt-原bnp
CN103163295B (zh) * 2011-12-08 2015-11-18 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法
RU2673074C2 (ru) * 2011-12-15 2018-11-22 Майкартис Н.В. Биомаркеры и параметры для определения гипертензивных расстройств при беременности
JP5814800B2 (ja) * 2011-12-28 2015-11-17 株式会社Ｌｓｉメディエンス 神経変性疾患の検出方法
ES2538226T3 (es) 2012-01-26 2015-06-18 F. Hoffmann-La Roche Ag Método para la diferenciación de la insuficiencia cardiaca anterógrada y retrógrada
EP2809393B1 (de) 2012-01-31 2016-11-30 Cardiac Pacemakers, Inc. Steuerungssystem und verfahren zur steuerung des betriebs von einem kardialen resynchronisationsgerät/therapie mittels biomarker daten
US20130196870A1 (en) * 2012-01-31 2013-08-01 Medical University Of South Carolina Systems and methods using biomarker panel data
EP2650684A1 (de) 2012-04-10 2013-10-16 Roche Diagniostics GmbH Diagnose auf Pro-SP-B und NT-proBNP bei Patienten mit Lungenentzündung
US8903480B2 (en) 2012-04-11 2014-12-02 Siemens Medical Solutions Usa, Inc. System for cardiac condition detection using heart waveform area associated analysis
WO2013163269A1 (en) * 2012-04-24 2013-10-31 Sri International Human serum biomarkers of prostate cancer and sars-cov
EP2615459A1 (de) 2012-04-27 2013-07-17 Roche Diagniostics GmbH Verfahren zur Diagnose von Distalbronchoalveolargewebeschäden in Asthma durch Erkennen von proSP-B
US20150141278A1 (en) * 2012-05-30 2015-05-21 Clarient Diagnostic Services, Inc. Multiplexed assay method for lung cancer classification
WO2013183725A1 (ja) * 2012-06-06 2013-12-12 国立大学法人九州大学 非ヒトモデル動物、非ヒトモデル動物の作製方法及び抗血栓薬のスクリーニング方法
EP2600155A1 (de) 2012-06-18 2013-06-05 Roche Diagniostics GmbH sFlt-1-basierte Diagnose und Überwachung von Schlaganfallpatienten
EP2597466A1 (de) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Mittel und Verfahren zur proSP-B-basierten Diagnose von Alveolenbeschädigung bei Patienten mit pulmonaler Hypertonie
EP2597467A1 (de) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Mittel und Verfahren zur proSP-B-basierten Diagnose von Lungenstauung bei Patienten mit akutem Koronarsyndrom
WO2014009418A1 (en) 2012-07-10 2014-01-16 Roche Diagnostics Gmbh TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
EP3428649B1 (de) 2012-09-12 2022-03-23 Roche Diagnostics GmbH Identifizierung von patienten mit abnormaler fraktionsverkürzung
ES2676737T3 (es) * 2012-10-02 2018-07-24 Sphingotec Gmbh Método para predecir el riesgo de contraer cáncer o para diagnosticar cáncer en un sujeto femenino
US20140273273A1 (en) 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
CN108120837B (zh) 2012-11-09 2021-06-22 霍夫曼-拉罗奇有限公司 阵发性心房纤颤的基于TnT的诊断
EP2730923A1 (de) 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen
EP2925337B1 (de) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
ES2672255T3 (es) 2012-12-04 2018-06-13 F. Hoffmann-La Roche Ag Biomarcadores en la selección de tratamiento para la insuficiencia cardíaca
DE102012223378A1 (de) * 2012-12-17 2014-06-18 Charité - Universitätsmedizin Berlin In-vitro Verfahren und Kit zur Diagnose von akutem Koronarsyndrom
KR20150099775A (ko) * 2012-12-20 2015-09-01 국립대학법인 홋가이도 다이가쿠 전립선 기저세포의 검출 방법
WO2014121252A1 (en) * 2013-02-04 2014-08-07 The General Hospital Corporation Biomarkers for stroke diagnosis
KR101494882B1 (ko) * 2013-02-21 2015-02-25 한국과학기술연구원 급성 심근 경색 진단용 조성물, 그 조성물을 포함하는 급성 심근 경색 진단용 키트 및 급성 심근 경색 진단 방법
US9020583B2 (en) 2013-03-13 2015-04-28 Siemens Medical Solutions Usa, Inc. Patient signal analysis and characterization
EP2866033A1 (de) 2013-10-23 2015-04-29 Roche Diagniostics GmbH Differenzialdiagnose von akuter Atemnot auf Basis von c-terminiertem proSP-B, KL-6 und BNP-Peptiden
WO2015066035A1 (en) * 2013-10-28 2015-05-07 The Forsyth Institute Compositions and methods for evaluating metabolic syndrome and related diseases
EP3066476A2 (de) 2013-11-04 2016-09-14 The Regents of the University of Michigan Biomarker und verfahren zur progressionsvorhersage für chronische nierenerkrankung
WO2015072865A1 (en) * 2013-11-15 2015-05-21 Lee Jacqueline Amanda Biomarker for cardiac disorders
WO2015112960A1 (en) * 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
EP3470848A3 (de) 2014-01-28 2019-05-22 Roche Diagnostics GmbH Biomarker zur risikobewertung und behandlungsüberwachung bei patienten mit herzinsuffizienz durch natriuretische peptide
EA201691682A1 (ru) 2014-02-21 2017-02-28 Эпик Сайенсиз, Инк. Способы анализирования редких циркулирующих в крови клеток
EP2916134B1 (de) 2014-03-05 2017-08-16 Roche Diagnostics GmbH Verwendung von Seprase zur Differenzialdiagnose von akuter Atemnot
EP3413052B1 (de) 2014-03-26 2022-12-28 Roche Diagnostics GmbH Igfbp7 zur diagnose von diastolischer dysfunktion
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
CA2973116C (en) * 2015-01-09 2023-08-15 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
CA3013316A1 (en) 2016-02-04 2017-08-10 Metanomics Gmbh Means and methods for differentiating between heart failure and pulmonary disease in a subject
AU2017246588A1 (en) * 2016-04-08 2018-09-27 Centre National De La Recherche Scientifique - Cnrs - Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
ES2817087T3 (es) 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
WO2018069487A1 (en) 2016-10-14 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of loss of renal function in patients with type 2 diabetes
WO2018127372A1 (en) 2016-12-13 2018-07-12 Witteman Johanna Cornelia Maria Detection of transient troponin peaks for diagnosis of subjects at high risk of cardiovascular disease
EP3360570A1 (de) 2017-02-13 2018-08-15 Roche Diagnostics GmbH Monoklonale antikörper für nt-probnp punktmutationen
US20210018507A1 (en) * 2018-03-04 2021-01-21 Mazumdar Shaw Medical Foundation Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
US20220178945A1 (en) * 2018-03-30 2022-06-09 Eiken Kagaku Kabushiki Kaisha Novel aortic aneurysm marker
EP3572813A1 (de) * 2018-05-22 2019-11-27 Centre National de la Recherche Scientifique Diagnoseverfahren von multipler sklerose
IT201800007264A1 (it) * 2018-07-17 2020-01-17 Metodo per la diagnosi in vitro di carcinoma della prostata mediante biomarcatori urinari
KR20210038893A (ko) 2018-07-31 2021-04-08 에프. 호프만-라 로슈 아게 심방 세동의 평가에서 순환하는 dkk3(딕오프 관련 단백질 3)
KR20210044216A (ko) 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
BR112021002725A2 (pt) 2018-08-16 2021-07-20 F. Hoffmann-La Roche Ag métodos para avaliar a fibrilação atrial, para prever o risco de acidente vascular cerebral, para avaliar a eficácia de uma terapia, para identificar um paciente, para monitorar a terapia de anticoagulação e para auxiliar na avaliação da fibrilação atrial, método implementado por computador, kit e uso in vitro
CN113260863A (zh) 2018-08-17 2021-08-13 豪夫迈·罗氏有限公司 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10)
WO2020039001A1 (en) 2018-08-22 2020-02-27 Roche Diagnostics Gmbh Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
WO2020039085A1 (en) 2018-08-24 2020-02-27 Roche Diagnostics Gmbh Circulating fgfbp-1 (fibroblast growth factor-binding protein 1) in the assessment of atrial fibrillation and for the prediction of stroke
WO2020064995A1 (en) 2018-09-28 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes
CN111192687A (zh) * 2018-11-14 2020-05-22 复旦大学附属儿科医院 一种进展期阑尾炎列线图预测模型及其用途
EP3914913A1 (de) * 2019-02-21 2021-12-01 B.R.A.H.M.S GmbH Verfahren zur diagnose von macce bei patienten nach einer gastrointestinalen chirurgie
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
US12461113B2 (en) 2019-05-23 2025-11-04 Roche Diagnostics Operations, Inc. IGFBP7 ratio for HFpEF
JP2022544169A (ja) * 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド 心血管疾患の処置および予防
JP7791093B2 (ja) 2020-02-20 2025-12-23 ユニベルシテイト マーストリヒト 循環ｂｍｐ１０（骨形成タンパク質１０）の検出方法
CN116547537A (zh) 2020-07-29 2023-08-04 皮克托有限公司 SARS-CoV-2抗体免疫测定
WO2022069658A1 (en) 2020-09-30 2022-04-07 F. Hoffmann-La Roche Ag Circulating total-nt-probnp (glycosylated and unglycosylated nt-probnp) and its ratio with nt-probnp (unglycosylated nt-probnp) in the assessment of atrial fibrillation
CN114182010B (zh) * 2022-01-11 2022-06-07 首都医科大学附属北京朝阳医院 一种血浆外泌体circRNA标志物及其应用
CN118922721A (zh) 2022-03-18 2024-11-08 豪夫迈·罗氏有限公司 用于2型与1型急性心肌梗死的早期辨别的cMyBPC标志物组合
JP2025508481A (ja) 2022-03-18 2025-03-26 エフ． ホフマン－ラ ロシュ アーゲー ２型対１型の急性心筋梗塞の早期識別のためのトロポニンマーカーの組合せ
CN115356486A (zh) * 2022-08-19 2022-11-18 华中科技大学同济医学院附属同济医院 一种变异型心绞痛的辅助诊断试剂、试剂盒及其应用
WO2024100050A1 (en) 2022-11-07 2024-05-16 Hôpitaux Universitaires Saint-Louis-Lariboisière Rapid optimization of oral heart failure therapies helped by nt-probnp testing
EP4365598A1 (de) 2022-11-07 2024-05-08 Hôpitaux Universitaires Saint-Louis-Lariboisière Schnelle optimierung von oralen herzinsuffizienztherapien mithilfe von nt-probnp-tests
CN115902237B (zh) * 2022-11-09 2024-09-27 哈尔滨医科大学 用于判断急性心肌梗死后心源性猝死的生物标志物及其应用
WO2024160752A1 (en) 2023-01-30 2024-08-08 F. Hoffmann-La Roche Ag Effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease
WO2024190857A1 (ja) * 2023-03-15 2024-09-19 住友ベークライト株式会社 動脈硬化性疾患を診断するための試薬および方法
CN121713069A (zh) 2023-08-22 2026-03-20 豪夫迈·罗氏有限公司 间质液中心血管标志物的监测及其在心力衰竭评定中的应用
CN121713064A (zh) 2023-08-23 2026-03-20 豪夫迈·罗氏有限公司 电化学免疫测定
EP4685484A1 (de) 2024-07-25 2026-01-28 Target Cells Spólka z ograniczona odpowiedzialnoscia Verfahren, assay und verwendung von saueren alpha-1 glykoprotein zur bestimmung der bindungskapazität von stammzellen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5453359A (en) 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5422393A (en) 1988-07-11 1995-06-06 Naturon Pharmaceutical Corporation Natriuretic hormone
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
JP3394040B2 (ja) 1989-06-23 2003-04-07 ジェネンテック・インコーポレーテッド ナトリウム排泄増加性蛋白質受容体ｂの組成物および合成法および使用法
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
CA2027434C (en) * 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US6147688A (en) 1993-06-28 2000-11-14 Athena Design Systems, Inc. Method and apparatus for defining and selectively repeating unit image cells
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
CA2248140C (en) 1996-03-04 2005-02-01 Ronald P. Mischak Assay and reagents for quantifying hbnp
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU728558B2 (en) 1997-04-30 2001-01-11 Maruha Nichiro Seafoods, Inc. Method for detecting or predicting ischemic diseases
US6117644A (en) 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6171870B1 (en) 1998-08-06 2001-01-09 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AU761451B2 (en) 1998-09-29 2003-06-05 Vladimir Berezin NCAM binding compounds
CA2263063C (en) 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AT407580B (de) 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
AUPQ893300A0 (en) 2000-07-21 2000-08-17 Newbrain Technologies Pty Limited Method and system for utilising database information
US6670138B2 (en) 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
JP4300108B2 (ja) 2001-06-27 2009-07-22 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
US6627457B2 (en) 2001-07-30 2003-09-30 Quest Diagnostics Investments Incorporated Methods for detecting pregnancy
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.

Also Published As

Publication number Publication date
JP2005121664A (ja) 2005-05-12
EP1666881B1 (de) 2010-02-17
US7361473B2 (en) 2008-04-22
JP3806694B2 (ja) 2006-08-09
WO2002089657A3 (en) 2003-02-27
AU2002305394A1 (en) 2002-11-18
DE60233301D1 (de) 2009-09-24
EP1322957A2 (de) 2003-07-02
US20060063204A1 (en) 2006-03-23
EP1322957B1 (de) 2009-08-12
JP2006234823A (ja) 2006-09-07
DE60235416D1 (de) 2010-04-01
ATE439588T1 (de) 2009-08-15
EP2261669A1 (de) 2010-12-15
US20030109420A1 (en) 2003-06-12
WO2002089657A2 (en) 2002-11-14
EP1666881A3 (de) 2007-09-19
JP2004520598A (ja) 2004-07-08
JP4235652B2 (ja) 2009-03-11
US7358055B2 (en) 2008-04-15
CA2414073A1 (en) 2002-11-14
EP1322957A4 (de) 2005-11-02
EP1666881A2 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
ATE458199T1 (de) Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
DE602004001533D1 (de) Immunotestverfahren für Herz-Troponin I
Leff et al. Further concerns over Cheng-Prusoff analysis
WO2001057522A3 (en) Immunochromatographic methods which employ semiconductor nanocrystals
DK0539477T3 (da) Fremgangsmåde til forstærkning af emissionssignalet af en luminescerende forbindelse
DE60227763D1 (de) Verwendung eines natriuretischen peptids vom b-typ als prognostischer indikator bei akuten koronaren syndromen
ATE496298T1 (de) Methode um die sensitivität einer luminesenz assay zu erhöhen
DK1423541T3 (da) Fremgangsmåde til at bestemme multiple analytter
ATE335763T1 (de) Sandwich-immunoassay zur bestimmung von proanp- teilpeptiden
ATE240522T1 (de) Chemilumineszenz-immunoassay zum nachweis eines mit der chagas-erkränkung verbundenen analyts in einer probe
AU3534001A (en) Method for identifying a mark applied on a solid body
DE59009452D1 (de) Verwendung von zweiwertigen Kationen in immunchemischen Tests.
ATE284955T1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE466884T1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
DK1567661T3 (da) Fremgangsmåder, biosensorer og sæt til detektion og identificering af svampe
DE68924141D1 (de) Geminale Diphenyl-Derivate und ihre Verwendung in Immunotests.
RU2001123102A (ru) Способ эксплуатации двигателя
DK1210606T3 (da) Bruskresorptionsassays
RU2001133157A (ru) Способ оценки микротвердости
DE50011831D1 (de) Dynamische bestimmung von analyten durch arrays auf inneren oberflächen
ES2063732T1 (es) Equipo y ensayo para determinar un antigeno/anticuerpo en una muestra.
DE50307060D1 (de) Verbesserung der Spezifität bei der Bestimmung von Antithrombin III
ATE163229T1 (de) Verfahren zur immunologischen bestimmung eines oder mehrerer analyten
EP0896209A3 (de) Verfahren zur Zuverlässigkeitsfeststellung einer mittels eines Krigingverfahrens auf einer Operationsgrösse einer Machine durchgeführte, auf Fehler in der Machine hinweisende, Tendenzanalyse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties